Total Payments
$2,747
2024 Payments
$62.61
Companies
9
Transactions
22
Medicare Patients
1,781
Medicare Billing
$108,248
Payment Breakdown by Category
Other$2,220 (80.8%)
Food & Beverage$389.05 (14.2%)
Research$98.78 (3.6%)
Travel$26.30 (1.0%)
Education$12.55 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,220 | 4 | 80.8% |
| Food and Beverage | $389.05 | 13 | 14.2% |
| Unspecified | $98.78 | 2 | 3.6% |
| Travel and Lodging | $26.30 | 2 | 1.0% |
| Education | $12.55 | 1 | 0.5% |
Payments by Type
General
$2,648
20 transactions
Research
$98.78
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $2,220 | 4 | $0 (2019) |
| Incyte Corporation | $139.62 | 5 | $0 (2018) |
| GlaxoSmithKline, LLC. | $121.54 | 3 | $0 (2024) |
| Exelixis Inc. | $75.00 | 1 | $0 (2018) |
| Janssen Pharmaceuticals, Inc | $60.86 | 4 | $0 (2020) |
| Celgene Corporation | $42.55 | 1 | $0 (2017) |
| Kestra Medical Technology Services, Inc. | $39.85 | 1 | $0 (2024) |
| Amgen Inc. | $34.71 | 2 | $0 (2020) |
| Biogen, Inc. | $12.55 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $62.61 | 2 | Kestra Medical Technology Services, Inc. ($39.85) |
| 2020 | $66.39 | 4 | Amgen Inc. ($34.71) |
| 2019 | $649.18 | 3 | PFIZER INC. ($620.00) |
| 2018 | $1,827 | 10 | PFIZER INC. ($1,600) |
| 2017 | $141.33 | 3 | GlaxoSmithKline, LLC. ($98.78) |
All Payment Transactions
22 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Kestra Medical Technology Services, Inc. | Assure WCD (Device) | Food and Beverage | Cash or cash equivalent | $39.85 | General |
| Category: Cardiology | ||||||
| 02/07/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY | Food and Beverage | In-kind items and services | $22.76 | General |
| Category: VACCINES | ||||||
| 08/26/2020 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $14.95 | General |
| Category: Bone Health | ||||||
| 07/15/2020 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $19.76 | General |
| Category: Bone Health | ||||||
| 02/28/2020 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $14.49 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 01/03/2020 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $17.19 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 12/05/2019 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $16.05 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 10/25/2019 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $13.13 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 03/23/2019 | PFIZER INC. | TALZENNA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $620.00 | General |
| Category: ONCOLOGY | ||||||
| 12/15/2018 | PFIZER INC. | TALZENNA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $330.00 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2018 | PFIZER INC. | TALZENNA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $940.00 | General |
| Category: ONCOLOGY | ||||||
| 07/03/2018 | PFIZER INC. | TALZENNA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $330.00 | General |
| Category: ONCOLOGY | ||||||
| 04/28/2018 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $75.00 | General |
| Category: Oncology | ||||||
| 04/20/2018 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $45.36 | General |
| 04/20/2018 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $42.97 | General |
| 04/20/2018 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $24.99 | General |
| 04/20/2018 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $24.30 | General |
| 04/20/2018 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $2.00 | General |
| 02/14/2018 | Biogen, Inc. | SPINRAZA (Biological) | Education | In-kind items and services | $12.55 | General |
| Category: NEUROLOGY | ||||||
| 02/21/2017 | GlaxoSmithKline, LLC. | — | — | Cash or cash equivalent | $57.76 | Research |
| Study: A Clinical Outcomes Study to compare the effect of Fluticasone Furoate Vilanterol Inhalation Powder 100 25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease COPD and a history of or at increased risk for cardiov | ||||||
| 02/21/2017 | GlaxoSmithKline, LLC. | — | — | Cash or cash equivalent | $41.02 | Research |
| Study: A Clinical Outcomes Study to compare the effect of Fluticasone Furoate Vilanterol Inhalation Powder 100 25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease COPD and a history of or at increased risk for cardiov | ||||||
| 01/22/2017 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | In-kind items and services | $42.55 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Clinical Outcomes Study to compare the effect of Fluticasone Furoate Vilanterol Inhalation Powder 100 25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease COPD and a history of or at increased risk for cardiov | GlaxoSmithKline, LLC. | $98.78 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 449 | 615 | $69,630 | $38,327 |
| 2022 | 13 | 516 | 654 | $47,015 | $28,439 |
| 2021 | 12 | 583 | 710 | $45,865 | $30,881 |
| 2020 | 8 | 233 | 349 | $29,680 | $10,600 |
Total Patients
1,781
Total Services
2,328
Medicare Billing
$108,248
Procedure Codes
47
All Medicare Procedures & Services
47 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 59 | 103 | $20,600 | $10,146 | 49.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 38 | 38 | $8,500 | $5,140 | 60.5% |
| 91320 | Sarscv2 vac 30mcg trs-suc im | Office | 2023 | 32 | 32 | $7,900 | $4,111 | 52.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 22 | 29 | $7,250 | $3,904 | 53.8% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2023 | 22 | 22 | $5,700 | $3,832 | 67.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 33 | 47 | $7,050 | $3,307 | 46.9% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 27 | 43 | $3,125 | $1,716 | 54.9% |
| 90480 | Admn sarscov2 vacc 1 dose | Office | 2023 | 32 | 32 | $1,600 | $1,401 | 87.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 19 | 29 | $2,900 | $1,241 | 42.8% |
| 90674 | Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | Office | 2023 | 30 | 32 | $1,600 | $1,066 | 66.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 30 | 32 | $1,600 | $1,051 | 65.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 74 | 137 | $685.00 | $671.30 | 98.0% |
| 0124A | Adm sarscv2 bvl 30mcg/.3ml a | Office | 2023 | 17 | 17 | $680.00 | $666.40 | 98.0% |
| 81002 | Urinalysis, manual test | Office | 2023 | 14 | 22 | $440.00 | $75.02 | 17.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 39 | 67 | $13,400 | $6,233 | 46.5% |
| 0004A | Adm sarscov2 30mcg/0.3ml bst | Office | 2022 | 109 | 110 | $4,400 | $4,366 | 99.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 20 | 26 | $6,400 | $3,451 | 53.9% |
| 0124A | Fee covid-19 vac 13 res | Office | 2022 | 83 | 83 | $3,320 | $3,254 | 98.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 23 | 41 | $6,150 | $2,888 | 47.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 11 | 11 | $3,300 | $2,034 | 61.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 22 | 35 | $3,500 | $1,570 | 44.8% |
| 0064A | Adm sarscov2 50mcg/0.25mlbst | Office | 2022 | 33 | 33 | $1,320 | $1,310 | 99.3% |
| 0134A | Fee covid-19 vac 14 res | Office | 2022 | 29 | 29 | $1,160 | $1,137 | 98.0% |
| 90674 | Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | Office | 2022 | 27 | 27 | $1,350 | $852.32 | 63.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 27 | 27 | $1,350 | $838.71 | 62.1% |
About Dr. Marc Saltzman, M.D
Dr. Marc Saltzman, M.D is a Hematology & Oncology healthcare provider based in Aventura, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1750379897.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Marc Saltzman, M.D has received a total of $2,747 in payments from pharmaceutical and medical device companies, with $62.61 received in 2024. These payments were reported across 22 transactions from 9 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2,220).
As a Medicare-enrolled provider, Saltzman has provided services to 1,781 Medicare beneficiaries, totaling 2,328 services with total Medicare billing of $108,248. Data is available for 4 years (2020–2023), covering 47 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Internal Medicine
- Location Aventura, FL
- Active Since 10/12/2005
- Last Updated 04/04/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1750379897
Products in Payments
- TALZENNA (Drug) $2,220
- Cabometyx (Drug) $75.00
- XARELTO (Drug) $60.86
- Abraxane (Drug) $42.55
- Assure WCD (Device) $39.85
- EVENITY (Biological) $34.71
- SHINGRIX (Biological) $22.76
- SPINRAZA (Biological) $12.55
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Aventura
Alejandra Del Toro, M.d, M.D
Hematology & Oncology — Payments: $18,346
Hematology & Oncology $18,346
Miss. Jennifer Cudris Maldonado, M.d, M.D
Hematology & Oncology — Payments: $12,626
Hematology & Oncology $12,626
Gelenis Domingo, M.d, M.D
Hematology & Oncology — Payments: $5,908
Hematology & Oncology $5,908
Dr. Enrique Davila, Md, MD
Hematology & Oncology — Payments: $1,098
Hematology & Oncology $1,098
Robert Hirsch, Md, MD
Hematology & Oncology — Payments: $985.48
Hematology & Oncology $985.48
Dr. Jonathan Leslie, D.o, D.O
Hematology & Oncology — Payments: $25.31
Hematology & Oncology $25.31